BRKR
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker\'s high-performance scienti c instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology.
Bruker Corporation (BRKR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Revisions (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | C+ (2.8) | C- (2.1) | B- (3.0) | B+ (3.7) | D+ (1.7) | C+ (2.7) |
| 2026-11-09 | C+ (2.8) | C- (2.1) | B- (3.0) | B+ (3.7) | D+ (1.7) | C+ (2.7) |
| 2026-11-06 | B- (2.9) | C- (2.1) | B- (3.0) | B+ (3.6) | D+ (1.5) | C+ (2.6) |
| 2026-11-05 | B- (2.9) | C- (2.1) | B- (3.0) | B+ (3.5) | D+ (1.5) | C+ (2.6) |
| 2026-11-02 | B- (2.9) | C- (2.1) | B- (3.0) | B+ (3.5) | D- (0.8) | C (2.5) |